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Background: Organotypic tumor spheroids, a 3D in vitro model derived from patient tumor material, preserve
tissue heterogeneity and retain structural tissue elements, thus replicating the in vivo tumor more closely than
commonly used 2D and 3D cell line models. Such structures harbour tumorigenic cells, as revealed by xenograft
implantation studies in animal models and maintain the genetic makeup of the original tumor material. The aim of
our work was a morphological and proteomic characterization of organotypic spheroids derived from colorectal
cancer tissue in order to get insight into their composition and associated biology.
Results: Morphological analysis showed that spheroids were of about 250 μm in size and varied in structure, while
the spheroid cells differed in shape and size and were tightly packed together by desmosomes and tight junctions.
Our proteomic data revealed significant alterations in protein expression in organotypic tumor spheroids cultured
as primary explants compared to primary colorectal cancer tissue. Components underlying cellular and tissue
architecture were changed; nuclear DNA/ chromatin maintenance systems were up-regulated, whereas various
mitochondrial components were down-regulated in spheroids. Most interestingly, the mesenchymal cells appear to
be substantial component in such cellular assemblies. Thus the observed changes may partly occur in this cellular
compartment. Finally, in the proteomics analysis stem cell-like characteristics were observed within the spheroid
cellular assembly, reflected by accumulation of Alcam, Ctnnb1, Aldh1, Gpx2, and CD166. These findings were
underlined by IHC analysis of Ctnnb1, CD24 and CD44, therefore warranting closer investigation of the tumorigenic
compartment in this 3D culture model for tumor tissue.
Conclusions: Our analysis of organotypic CRC tumor spheroids has identified biological processes associated with a
mixture of cell types and states, including protein markers for mesenchymal and stem-like cells. This 3D tumor model
in which tumor heterogeneity is preserved may represent an advantageous model system to investigate novel
therapeutic approaches.
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Preclinical cancer research has thrived on in vitro cultur-
ing systems. However, it has become increasingly clear
that long term monolayer cultures used to study mo-
lecular and biological aspects of tumor cells, as well as
their response to therapeutic agents, have lost a great
many features exhibited by in vivo tumors. In cell mono-
layers, the architecture of a tumor tissue and the com-
plex connections and interactions of its constituent cell
types and matrix molecules are largely lost, intratumoral
differences in nutrition, oxygenation, and drug penetra-
tion are abrogated, and growth on a plastic substratum
can induce significant changes in cellular genotype and
phenotype.
In contrast, three-dimensional cell culture systems have
biological characteristics which are more closely related to
those of in vivo tissue [1-4]. Spherical, multicellular aggre-
gates called spheres can be grown from established cell
lines or dissociated tissue cells in serum-free medium
containing appropriate growth factors [5-9]. In recent
years, sphere growth has become the basis of clonogeni-
city assays used to score for cancer stem cell-like cells
(CSC). The latter are thought not only to underlie
spheroid growth in vitro, but also to fuel tumor growth
(and recurrence) in vivo, producing a similarly hetero-
geneous progeny of more differentiated cell types in
both cases. Self-renewing at a relatively slow rate, CSCs
are assumed to maintain an undifferentiated, damage-,
apoptosis- and drug-resistant compartment of tumor-
initiating cells. Thus, in contrast to their differentiated
progeny, CSCs are clonogenic in vitro and tumorigenic
in vivo, and therefore appear to be the main culprits in
cancer biology. However, stem cell (−like) behavior may
be a dynamic rather than a static property, i.e. a feature
that can be adopted by more differentiated cells through
interactions with the stromal environment [10] and/or
through epithelial-mesenchymal transition (EMT) pro-
cesses [11]. The Lgr5-positive crypt base columnar cell
was suggested to represent the stem cell of the small
intestine and colon [12]. It has also been described for
normal colon biology that the transfer of stem cells be-
tween the border and central regions of crypts, endows
all Lgr5+ colon stem cells with long-term self-renewal
potential through which a heterogeneous cell popula-
tion is able to function long term as a single stem-cell
pool [13]. In mice, the Lgr5-expressing colon stem cells
depend on stem cell niche signals provided by a special-
ized daughter cell, the (CD24+)Paneth cell [14,15]. The
colon CSC compartment maintenance may depend on
equivalent niche signals.
Detailed cellular and molecular characterization of CSCs,
including their specific protein expression profiles, may
lead to a better understanding of tumor biology, and
provide novel biomarkers and targets for therapeuticprocedures. Different markers have been proposed for
the identification of colorectal CSCs, including CD133
(Prominin-1), CD166 (Alcam), CD44, EpCAM, CD24,
CD29 (Integrin beta-1) and others [16] as well as the
Lgr5 protein found in normal intestinal stem cells
[16-21]. In addition to these cell surface markers, the
use of intracellular markers involved in epithelial devel-
opment and differentiation has been proposed to iden-
tify CSCs [22-24]. For example, Wnt signaling cascades,
where nuclear b-catenin is one of the key players
(reviewed in [16]), have important roles in the homeo-
static self renewal of the intestine as well as in colorec-
tal carcinogenesis. Thus, their role in colorectal cancer
‘stemness’ has received particular attention [25-27].
Spheroids can not only be generated from (dissociated)
cultured cells, but also directly from tissue biopsy frag-
ments in an organ culture type of fashion [28-32]. Im-
portantly, these “tumor tissue spheroids” preserve tissue
characteristics of the original tumor in situ that are not
only lost in monolayer cultures of cell lines, but also in
spheroids derived from dissociated tissue cells. Specifically,
tissue elements such as extracellular matrix, capillaries,
connective tissue, and immune cells can be demonstrated
in such ‘organotypic’ spheroids as well as tumor cell
heterogeneity [28]. These tissue spheroids still preserve
tumor-initiating potential as demonstrated by xenograft-
ing experiments in animal models, where they generated
stem-like tumor phenotype [33]. Moreover, in case of
glioblastoma, the spheroids themselves display some
features of stemness evident in the expression of cer-
tain markers and cell growth patterns [33]. In addition to
that, in colorectal cancer research tissue culture protocols
were reported that allow the isolation and propagation of
tumor-derived 3D-spheroid/organoid cultures that are
enriched in CSCs [19,23,34,35]. It is also well known that
genomic profiles of long term cell cultures frequently devi-
ate from parental tumor profiles, whereas spheroids are
genetically more stable and representative of the original
tumor [36]. Therefore, with a complexity that is lower
than that of the original tumor, but higher than that of
other in vitro culture systems, organotypic tissue spher-
oids could be used to maintain and study tumor-like tissue
and test therapeutic agents in vitro in a more relevant
setting. Recently, successful 3D culture system was also
described that allows long-term expansion of adult
small intestine, stomach and liver cells without the need
of a mesenchymal niche, while preserving the character-
istics of the original adult epithelium [37-39] using the
Wnt agonist RSPO1 in culture medium [40-43].
Here, we have established colorectal carcinoma (CRC)
spheroid cultures from patient resection material. These
spheroids develop into an outer layer of epithelial-like
cells and an inner core of mesenchymal-like cells. To
characterize the spheroid-specific protein repertoire and
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at the protein level, we have performed an in-depth dif-
ferential proteomics analysis of CRC tissue spheroids
versus the original tissue resection material from which
they were derived. To the best of our knowledge, this is
the first in-depth proteomics characterization of primary
tumor (tissue) spheroids that includes identification and
relative quantification of a significant set of proteins on a
high-end mass spectrometric platform. Biological network
and pathway analysis of proteins that were differential be-
tween tumor spheroids and their parental tumors indicate
that nuclear (chromatin, DNA, and RNA regulatory) pro-
teins, cytoskeletal and cell-cell/cell-substratum interaction
proteins, are up-regulated, whereas mitochondrial and
metabolic processes are clearly down-regulated. Although
harboring a mixed population of cells and their associated
cellular processes, organotypic spheroids show elevation
of a number of putative markers associated with CSCs,
such as oxidative stress-induced proteins like Aldh1 and
Gpx2, and the cell surface marker CD166 (Alcam1) and
b-catenin. Therefore this system may prove relevant for
drug testing and yield novel drug targets and markers for
further testing in pre-clinical animal models.
Results and discussion
Tumor spheroid formation
We have generated tumor tissue spheroids from human
colorectal tumor resection material. Of 12 colon adeno-
carcinomas studied, 11 formed spheroids, usually after
2–5 days in culture. In contrast, normal colonic mucosa
always failed to form spheroids in culture. The number
of spheroids formed from each tumor depended on the
amount of biopsy material, but generally the number
of spheroids was over 30. Only tissue fragments that
formed spherical aggregates within 5 days in culture
were used for further study. Spheroid size varied be-
tween 150–350 μm in diameter and average size was
about 250 μm (Figure 1A). The spheroids from three
(Table 1; highlighted CC9, 11, 12) colon adenocarcinomas
that were further analyzed remained stable in size over
time in a 20-day culturing period. Also, when comparing
spheroids from different patients, no significant difference
in spheroid size could be discerned (Additional file 1:
Figure S1A).
Microscopical and immunohistochemical characterization
of tumor spheroids
Scanning electron microscopy of tumor tissue spheroids
revealed a somewhat variable spheroid structure, ranging
from a largely smooth surface (Figure 1A) to a more
blebby appearance (Figure 1B). This variation was ob-
served even for spheroids derived from the same tumor.
Also, structures that seemed to be the remnants of a
vessel were present on the surface of one spheroid (notshown). On a higher SEM magnification (Figure 1C), small
scale ‘brush’ structures can be seen on the spheroid
surface. In transmission electron microscopical images,
these structures were observed at the surface of periph-
eral cells (Figure 1D), with a rather irregular shape and
thickness (see higher magnification in Figure 1E). This
suggests that these cells preserve, to some extent, a
polarized epithelial-like character. TEM revealed a con-
siderable variation in shape and size of spheroid cells,
which were closely interconnected and joined by desmo-
somes (1E large arrow) and tight junctions (Figure 1F,
arrowhead). Characteristically, the nuclei were hyper-
chromatic and large, and the cytoplasm showed unusual
high numbers of vacuoles and structures similar to lyso-
somes (Figure 1D).
Figure 2 shows H&E stainings as well as immunohisto-
chemical characterization of CRC tissue biopsies and
biopsy-derived spheroids. Generally, as observed in TEM,
in H&E-stained sections spheroid cells were tightly packed
together (Figure 2A, B). Interestingly spheroids often
resumed a 3D structure that was reminiscent of the
intestinal tissue organization with an outer layer of cells,
one to five cells thick that seemed to be of an epithelial
nature. The epithelial character was confirmed by staining
for cytokeratin 20 (CK20/Krt20), an established marker
for colonic epithelial cells (Figure 2C, D). In contrast,
CK20 staining was undetectable in the central core of
spheroids. The converse was true for the mesenchymal
marker, vimentin (Vim), which was detected in the cen-
tral core, but not in the epithelial-like layer (Figure 2E, F).
To assess proliferative activity, spheroids were stained
for the proliferation marker, Ki-67/Mki67 (Figure 2G, H).
Whereas the proliferation index was calculated to be
51.6% for tumor tissue, it was only 5.5% within spher-
oids indicating that 10-day-old organotypic tumor
spheroids contain few cycling cells (Additional file 1:
Figure S1B), which is consistent with the absence of
spheroid growth over time. Figure 2I, J also shows an
example of tumor infiltrating immune cells, as revealed by
staining for the macrophage-associated CD68 marker,
that could still be found in spheroids (Figure 2J, sug-
gesting that the organotypic spheroid culture model still
retains non-neoplastic cells of the tumor microenviron-
ment and thus approximates the in vivo situation more
than monolayer cultures or monoclonal spheroids do. Given
the cellular ratio of epithelial-like versus mesenchymal-like
cells, it is to be expected that whole-spheroid analyses
will be dominated by the latter.
Differential proteomics of CRC tumor tissue and CRC
tissue spheroids
To assess relative differences in protein expression between
CRC tumor tissue and organotypic spheroids derived
thereof, lysates of tumor tissue as well as corresponding
Figure 1 Electron microscopy showing ultrastructure of the colorectal cancer spheroids under investigation. Scanning electron
micrograph of spheroids grown from different tumors (A, B) showing variation in surface architecture. Scale bars = 10 μm. The presence of
microvilli was revealed on greater magnification (C). Scale bar = 1 μm. (D-F) Transmission electron microscopy. Transmission electron micrograph
from a spheroid after 10 days of culture (D). Note the nuclear pleomorphism indicating tumor cell heterogeneity, and the presence of microvilli
(small arrow) at the apical surface of peripherally located cells (E). Cells were closely interrelated; tight junctions (large arrow) in (E) and
desmosome junctions (arrowhead) were observed between neighboring cells (F). Magnification: D; 2000×, E; 12000× and F; 15000×.
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tients. We set out to fractionate similar protein amounts
from each lysate on an SDS-PAGE gel (Additional file 2:
Figure S2), process individual gel slices through in-gel
tryptic digestion, and analyze the resultant tryptic peptide
mixtures using label-free nanoLC-MS/MS. Subsequently,
we performed database searching and spectral counting as
described before [44,45] to discern relative differences in
protein expression between different samples.Our analysis yielded a dataset of 1366 IPI database
entries (1315 unique proteins) that were identified across
all samples (see Materials and Methods for identification
criteria). In each group, the overlap of protein identifica-
tion across all three biological samples was over 50%
(Additional file 3: Figure S3). The majority (1133) of the
1315 proteins (86%) was found in both tumor tissue and
spheroids, whereas a minority was specific to either
sample type (Figure 3A). This suggests a high similarity
Table 1 Clinical patient data and corresponding colorectal carcinoma samples grown as spheroids in vitro
Patient # Gender Age Tumor localizationa TNM Stage (I-IV) Spheroid formation
1 M 65 Distal III Yes
2 F 48 Distal II Yes
3 F 73 Distal II Yes
4 M 83 Distal III Yes
5 F 81 Proximal III Yes
6 M 69 Proximal II No
7 M 74 Distal III Yes
8 F 82 Distal II Yes
9 M 52 Proximal III Yes
10 M 85 Distal II Yes
11 F 56 Proximal III Yes
12 F 47 Distal III Yes
Samples of patients 9, 11, 12 (highlighted in red) were used for proteomics.
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tial details of the dataset are shown in Figure 3B. A sub-
set of 174 proteins exhibited > 1.5-fold change in each
of the pairs, and 105 proteins of those additionally
exhibited a more than twofold difference between tumor
tissues and spheroids (70 up-regulated, 35 down-regulated)
(Figure 3B). A supervised cluster analysis using these
174 differential proteins is shown in a heat map view in
Figure 3C. Two main clusters are discerned, correspond-
ing to the CRC tissue samples and the tissue spheroid
samples, respectively. The up-regulated proteins contained
a subset of 26 acute phase, coagulation, and complement
cascade proteins (Additional file 4: Table S1) that are at
least partly introduced by the medium used for spheroid
culturing, and were therefore not subjected to furtherFigure 2 Immunohistochemical staining of tumor biopsy and biopsy
staining with anti-CK20 (Krt20) antibody. Vimentin, staining with anti-vimen
CD68, staining with anti-CD68 antibody. See Materials and Methods for detanalysis. The remainder of the differentially expressed
proteins are listed in Tables 2A, 2B, 3A and 3B. The
whole dataset is provided in Additional file 5: Table S2.
Our proteomics data indicate an accumulation in
mesenchymal-like cells (as deduced from the twofold
up-regulation of the mesenchymal marker vimentin) and
a decrease in epithelial-like cells (as deduced from the
overall down-regulation of several markers: cytokeratin
20, mucin 2 (Muc2), and vilin 1 (Vil1)) in spheroids as
detailed in Additional file 5: Table S2). Epithelial markers
such as E-cadherin (Cdh1) see also (Figure 4) and Epcam
appear to be relatively unchanged. Loss of the former is
associated with tumor progression and invasion [46],
whereas the latter has been associated with the colonic
cancer stem cell (Co-CSC) compartment [19]. The farspheroid sections. HE, haematoxylin & eosin staining. Cytokeratin,
tin (Vim) antibody. Ki-67, staining with anti-Ki-67 (Mki67) antibody.
ails.
Figure 3 Summary of the protein expression data in colorectal tumors vs corresponding spheroids. (A) Venn diagrams illustrating
overlapping sets of unique proteins identified in CRC tissues and CRC spheroids derived thereof. (B) Tables denoting the number of differential
proteins, respectively, with different criteria for filtering. Abbreviations: CRC, colorectal tumor tissue; SPH, CRC spheroids; FC, fold change; Sp.
Count separated, number of proteins from the third column (p < 0.05 & FC > 2) that, in addition, exhibit spectral count separation: the lowest
spectral count in one group is higher than the highest spectral count in the other group. (C) Heat map view of a supervised cluster analysis
using differential proteins from the comparison CRC tissue and spheroid proteomes (174 proteins with 1.5 fold change in all 3 pairs). The protein
abundances were normalized to zero mean and unit variance for each protein. Two clusters are formed for the CRC tissue lysate and spheroid
groups. CRC, colorectal cancer; tissue sample; SPH, spheroid sample.
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(68 of 70) have a ratio of ~ 3 and higher while vimentin is
upregulated in spheroids only with a Fc of 1.9 (Table 2B,
3B). Therefore, the differential expression of most proteins
in our top list cannot be solely explained by the epithelial/
stroma ratio.
Protein network analysis for differential proteins
To obtain a first impression of the type (s) of regulated
proteins that are functionally interconnected in our data-
set, we fed the lists of Tables 2 and 3 to the web-based
STRING tool [47], which mines known and predicted
protein interactions. These networks were imported
and visualized in Cytoscape [48] (Figures 5 and 6), and
associated biological functions were explored using the
BINGO plugin for Cytoscape [49]) (Additional file 6:
Table S3). In the network of proteins up-regulated in
spheroids (Figure 5), one can discern [1] a set of pro-
teins involved in translation (Rpl11, Rpl21, Eif3i, Eif4h,Figure 4 Immunohistochemical staining of CRC biopsies and correspo
mesenchymal part of the spheroid. Scale bar is 100 μm for all images.Eef1b2); [2] a characteristic RNA splicing factor net-
work involved in binding, metabolism, and processing
of nuclear RNA (e.g., Hnrnpa0, Srsf3, Ddx17); [3] a layer
of interacting proteins involved in chromatin anchoring
and epigenetic/transcriptional regulation (Cbx3, Cbx5,
Set, Ilf3), DNA replication (Set, Pcna), or DNA repair
(Parp1, Pcna); [4] two interconnecting heat shock proteins
(HSPA4 and HSPB1) [5] a set of components involved in
cytoskeletal organization, organelle organization, cell-cell
interactions, and signal transmission, including Vim, talins
(Tln1, Tln2), the anti-mitogenic protein Rap1A, Rac1, and
Zyx; [6] tissue development proteins (including Tagln,
Csrp2, Rac1); and [7] a set of proteins involved in nitrogen
compound metabolism (PpIa, Tpi1, Mdh1, Nit2, Dpysl3)).
At a lower stringency level, by including proteins up-
regulated in spheroids in at least two out of three sample
pairs (Additional file 7: Table S4), further support is ob-
tained for an increase in: RNA splicing factors and proteins
involved in DNA replication, nucleosome reorganizationnding spheroids. The section shows mainly the internal,
Figure 5 Network of up-regulated proteins (referenced by gene symbols) in all CRC-SPH pairs. Proteins up-regulated with a fold
change > 1.5 in all three pairs of spheroids (SPH) versus their parent colorectal carcinoma tissue (CRC) were pre-screened with the BINGO
gene ontology tool, and inflammatory/acute phase-related proteins were deleted from the list. The remaining proteins were uploaded to
STRING, and the returned protein-protein link data were used to generate and annotate a protein network in Cytoscape. Nodes and their
labels were sized according to the number of edges connected to them. Node color was made dependent on the overall fold change in all
three CRC-SPH pairs: nodes exhibiting a defined fold change were colored along a white-to-blue gradient (minimum and maximum values
indicated), whereas nodes only detected in SPH were colored purple, see color legend.
Figure 6 Network of down-regulated proteins (referenced by gene symbols) in all CRC-SPH pairs. Proteins down-regulated with a fold
change > 1.5 in all three pairs of spheroids (SPH) versus their parent colorectal carcinoma tissue (CRC) were uploaded to STRING, and the returned
protein-protein link data were used to generate and annotate a protein network in Cytoscape. Nodes and their labels were sized according to
the number of edges connected to them. Node color was made dependent on the overall fold change in all three CRC-SPH pairs: nodes exhibiting a
defined fold change were colored along a white-to-green gradient (minimum and maximum value indicated for connected nodes), whereas nodes only
detected in SPH were colored black, see color legend. The unconnected PLIN2 node has a fold change of 24, but was given the color of the top of
the gradient.
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nuclear lamina/scaffold proteins (Lmnb1, Emd, Matr3,
Numa1, Ncl), proteins involved in shuttling between the
cell cortex/focal adhesions and the nucleus (δ-catenin
(Ctnnd1), Lpp, Ahnak), and the central Wnt pathway ef-
fector β-catenin (Ctnnb1). The latter protein has been
strongly implicated in ‘stemness’ of both normal and cancer
stem cells of the colon. Among the set of up-regulated
proteins in ≥ 2/3 pairs (Additional file 7: Table S4), we also
discern proteins involved in reducing cellular stress (Hsph1,
Gsto1, Gstm1, Gpx2, Aldh1a1). The latter two proteins
have been recently associated with, and proposed as
markers for, colonic CSCs [23].
Among the (core of) down-regulated proteins (Figure 6),
there is a preponderance of interconnected mitochondrial
enzymes involved in phosphorylation, fatty acid metabol-
ism, acetyl-CoA catabolism, and responses to reactive
oxygen species. This correlates with a reduced metabolic
rate, in particular a reduction in cell proliferation and in
oxidative phosphorylation, which is in agreement with the
slow cycling activity and the reduced oxygen tension
present in the spheroids. Some of the down-regulated pro-
teins are involved in reducing oxidative stress (Cat, Sod2,
Gsr), whereas others may contribute to such stress (e.g.
mitochondrial respiratory chain components) or apoptosis
(Tgm2). Overall mitochondrial activity seems to be signi-
ficantly reduced, although, interestingly, and against the
trend, both cytochrome c oxidize (Mt-co2) and one of
its biosynthetic chaperones (Sco1) are up-regulated. In
addition, a set of proteins associated with anatomical
structure development involving cell-substratum interac-
tions and extracellular matrix composition/modulation are
down-regulated (Lama4, Myl6b, Itga5, Phb2, Itgav, Tgm2,
Anxa1, Nid1, Hbb, Prelp). In all, the nature of the down-
regulated proteins suggests a reduction of mitochondrial
activity and a change in the cell-substratum interface, going
from CRC tumor tissue to spheroids in vitro. Furthermore,
the down-regulation of the Mpo peroxidase seems to in-
dicate a relative depletion of immune cells in spheroids.
Immunohistochemistry of selected spheroid-enriched
proteins
The expression of a number of proteins encountered in
the above charts has been further characterized through
immunohistochemical staining (Figure 4). These proteins
include the nuclear protein Parp1 involved in DNA repair
(Figure 4), and the nuclear and/or cytoplasmic Wnt
pathway components β-catenin and Rac1 implicated in
stemness (Figure 4). As expected these proteins could
be confirmed both in spheroids and the tumor biopsies,
further supporting the similarities between the samples.
Similar expression of Cdh1 in tissue vs spheroids as found
by proteomics was confirmed by IHC staining (Figure 4).
The proposed markers of cell stemness CD44 and CD24were also included in the IHC analysis and showed
slight increase in spheroids (Figure 4). Finally, the down-
regulation of the cell-cell-interaction protein LAMA4 in
the spheroids as determined by proteomics was con-
firmed by IHC (Figure 4), possibly indicating a more fluid
organization of ECM and cell-cell interactions in spheroids.
Functional implications of tumor spheroid analyses
Being able to study tumorigenic cells in their native niche,
but ex vivo, is invaluable for gleaning information about
basic cancer biology and tumor cell resistance, as well as for
early in vitro testing of new candidate anti-tumor drugs. Al-
though monolayer (2D) cultures of established cell lines and
spheroid (3D) cultures of both tumor cell lines and dissoci-
ated tumor tissue cells have provided us with useful infor-
mation, these models are of monoclonal origin and have lost
the complexity of a heterogeneous cancer tissue. Organoty-
pic spheroids such as used here, which preserve multicellu-
larity throughout the procedure and retain original tissue
elements [28], more closely resemble the tissue in vivo. Such
structures harbor tumor initiating cells, as revealed by xeno-
graft implantation studies in animal models [33]. According
to the CSC concept, such cells should exhibit characteristics
linked with ordinary stem cells, such as slow cycling [50],
enhanced DNA repair, chromatin maintenance and telomer-
ase activity [51], resistance to (oxidative) stress and apoptosis
[52-55], and drug detoxification and efflux (Additional file 5:
Table S2) [50]. Here, we have performed an initial proteomic
characterization of organotypic spheroids derived from CRC
tissue, which, following in vitro culture, appear to be
enriched in stem-like cells, while maintaining the cellular
complexity of the parental tumor.
The CRC tumor spheroids as grown here, exhibit at
least a dichotomy of cell types: the outer surface is made
up of epithelial-like cells, whereas the inner core contains
substantial part of mesenchymal-like cells recapitulating
the tissue of origin. The observed ultrastructural variability
(Figure 1A and B) might be explained by a differential
extent of (outer) extracellular matrix deposition/ remodel-
ing, a process that according to our proteomics data is
ongoing in spheroids relative to parental tumor tissue. In-
deed, as the generation of spheroids from primary tissue
will be accompanied by significant changes in cell and tis-
sue architecture, it is not unexpected that various proteins
associated with the extracellular matrix, the cell cortex,
and the cellular cytoskeleton are found upregulated in
spheroids (see Tables 2 and 3, Figures 5 and 6). Apart from
these changes, we observe up-regulation of specific pro-
teins associated with protein translation, RNA metabolism
(RNP components), and DNA/chromatin/chromosome
organization and maintenance, as well as down-regulation
of a significant set of mitochondrial proteins.
Ki-67 staining suggests that very little proliferative activ-
ity occurs in spheroids. When we inspect our differential
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the Pcna protein and the Mcm proteins, all classically
implicated in DNA replication. However, the above
molecules may serve more complex functions. Thus,
Mcm proteins are stably loaded onto chromatin in the
G1 phase, but require triggering of their helicase activity
and ensuing replication to unload; following replication
arrest, they remain bound indefinitely [56]. Pcna, a binding
partner for a plethora of proteins, and subject to diverse
post-translational modifications, has been dubbed the
“maestro of the replication fork”, and is involved in mul-
tiple processes including, besides DNA replication, DNA
repair, chromatin remodeling, sister-chromatid cohesion,
and cell cycle control [57,58]. These proteins may accu-
mulate in cell cycle arrested cells and thus, replication
does not necessarily have to be the major differential
DNA/chromatin-associated process when comparing CRC
tumor tissue with the spheroids grown from that tissue.
Indeed, it seems that the nuclear proteins upregu-
lated in spheroids form part of a larger array of pro-
teins involved in chromatin regulation/maintenance as
well as DNA repair. Cbx proteins have been classically
associated with epigenetic repression of gene expres-
sion (binding to histone H3 in silenced chromatin),
although they also seem to have a role in transcription
[59,60]. Furthermore, they are known to connect chroma-
tin to the nuclear lamina through the lamin B receptor
[61]. In our dataset, in the lower stringency analysis, Cbx3
(also known as HP1γ) and Cbx5 (also known as HP1α)
are both connected to the histone H3f3a variant (H3.3)
which is not only linked with active gene transcription
[62], but also with heterochromatin formation [63], and
possibly lineage priming in mesenchymal stem cells
[64]. Moreover, histones H2a (a nucleosome constitu-
ent) and HIST2H2BE Hist2h2be (both upregulated in
two out of three spheroid samples) play an important
role (may contribute to the formation of the functional
antimicrobial barrier of the colonic epithelium) in epi-
genetic control of stem cells [65]. It remains however, to
be analyzed whether the chromatin-modification reflects a
changing stress response. Furthermore, the Set protein
has been linked with inhibition of both HAT-dependent
transcription [66] and DNA demethylation [67], thus
enhancing gene silencing. Set is also an anti-apoptotic
component involved in caspase-independent apoptosis.
Another multifaceted protein that is upregulated in
spheroids is the DNA repair protein Parp1 [68,69]. One
of the additional roles of Parp1 is induction of repressed
chromatin [70], and it has also been associated with
telomere maintenance [71].
One of the nuclear spheroid proteins that warrants
follow-up studies as a candidate prognostic and drug
resistance biomarker in CRC is ILF3. ILF3 was also
identified as spheroid enriched protein in our previousproteomics screen of single cell-derived CRC spheres
[72]. This protein is a double-stranded RNA (dsRNA)
binding protein that complexes with other proteins,
dsRNAs, small noncoding RNAs, and mRNAs to regu-
late gene expression and stabilize mRNAs, and has an
emerging function in DNA repair. In translational stud-
ies, ILF3 was part of a gene signature that can predict
survival in lung cancer patients which is relevant for
the selection of patients for adjuvant therapy [73]. In
the latter study, ILF3 showed correlated mRNA and
protein overexpression in lung cancer development and
progression. In another study, ILF3 was part of a gene
expression pattern for doxorubicin (Adriamycin) resist-
ance where resistant breast tumors highly expressed
this gene [74]. In all, it appears that CRC tissue spher-
oids harbor chromatin maintenance and DNA repair
processes that are enhanced to some degree.
When inspecting the proteins that are down-regulated
in spheroids versus CRC tumor tissue, one is immedi-
ately struck by the widespread down-regulation of mito-
chondrial proteins, including multiple respiratory chain
components. Reprogramming of energy metabolism is
an emerging hallmark of cancer cells [75], and tumor
cell metabolism a relatively new focus of attention [76].
Metabolic reprogramming in response to hypoxia is as-
sociated with several well-known regulators implicated
in cancer biology, including p53, PI3K, NFκB, HIF1, and
Myc [77]. In this light it is of note that loss-of-function
mutations of fumarate hydratase (Fh) and succinate
dehydrogenase (Sdh) components (down-regulated in
our study, Figure 6) have been associated with certain
tumors, and that the resulting accumulation of fumar-
ate or succinate can counter the destruction of Hif1a [76].
Also, reduced conversion of acetyl-CoA (see Figure 6)
may make this key intermediary available for histone
acetyl transferases that mark the genome epigenetically
[78]. Shunting glucose into the pentose phosphate
pathway instead of mitochondrial oxidative phosphor-
ylation allows cells to generate NADPH, a key mol-
ecule in anti-oxidant defense [76]. The concomitant
down-regulation of anti-oxidant proteins such as Sod2
and Gsr (as well as peroxisomal Cat) may be overcome by
sufficient dampening of mitochondrial activity, as well as
by the up-regulation of oxidative stress-reducing proteins
such as Mgst3 [79], and Gpx2 [24]. Other proteins that we
found to be differential may also contribute to the detoxi-
fication of harmful compounds, such as Nit2 [80], Cbr1,
Aldh1a1, as well as other up-regulated dehydrogenases in
our dataset (Additional file 5: Table S2) [81,82]. In relation
to these defense mechanisms, cell survival through in-
hibition of apoptosis might also occur. Here, we see a
somewhat mixed picture: whereas pro-apoptotic mol-
ecules such as Pycard, and Pdcd5 exhibit elevated
levels, anti-apoptotic proteins such as Set and Hspb1
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of death-inducing proteins such as Diablo and Tgm2.
The latter protein is normally squelched by Gstp1
[83,84], a protein which is slightly up-regulated in our
dataset. Mitochondrial alterations may also affect the
role these organelles normally play in cellular apop-
tosis [85]. Together, our observations suggest that
CRC tumor spheroids try to ward off various forms of
cellular stress, including hypoxia.
We have detected increased levels of β-catenin (Ctnnb1)
a key component of the classical Wnt pathway [86,87], in
our spheroids (Additional file 7: Table S4). Both Parp1 and
Xrcc6 (also known as Ku70), proteins found in our dataset
to be up-regulated in spheroids, can bind to the Tcf4/β-
catenin transcription factor complex central to Wnt
signaling [88,89]. Since β-catenin has turned out to be a
hallmark protein defining “Wnt activity” and “stemness”
in colorectal stem cells and CSCs [10,86], one would sur-
mise that tumor spheroids, harboring tumor-initiating
cells, contain cells that display such activity. However,
“Wnt activity” is determined by nuclear localization of
the β-catenin protein [10,86], the extent of which we
cannot assess from our data.
In recent years, attempts have been made to characterize
(and sort) tumorigenic, colorectal CSCs through cell
surface markers such as CD133 (Prom1), CD166 (Alcam),
CD44, EpCAM, CD29 (Itgb1), and CD24 [17,18,21,22].
Especially the CD133 marker has received much focus
[18,19], but has become somewhat controversial [90], and
concerns have been raised regarding the antibody used to
detect the CD133 antigen [91]. Of the above, in our prote-
omics study, we have only detected Alcam as a differential
protein in 2 of 3 tissue-spheroid pairs, in addition to
CD44, which was only differential in one pair. We did,
however, also observe significantly differential levels for
the intracellular Aldh1a1 and Gpx2 proteins which were
recently associated with the colorectal CSC compartment
[23,24]. In line with the above, the IHC analyses of puta-
tive colorectal tumor stem cell markers showed increased
expression of Ctnnb1, CD24 and CD44 in spheroids vs
tumors by IHC (Figure 4) thus indicating the presence
of a cancer stem cell compartment.
Conclusions
In sum, collectively our data reveal significant similar-
ities between organotypic CRC spheroids and primary
CRC tumor tissue. The differences detected at the pro-
tein level include components underlying cellular and
tissue architecture; an upregulation of nuclear DNA/
chromatin maintenance systems and a down-regulation
of various mitochondrial components in spheroids. In
view of the substantial content of mesenchymal cells
in such cellular assemblies, these changes may largely
occur in this compartment. We have also observed somestem cell-like characteristics within the mix of different
cell types and cell states present in spheroids, including
Alcam, Aldh1, Gpx2, Ctnnb1, CD24, CD44, and CD166
warranting closer investigation of the tumorigenic com-
partment in this 3D culture model for tumor tissue as
well as the use for in vitro drug testing.
Patients, materials and methods
Patient tumor material
Tumor fragments were obtained after surgery from 12
patients with colorectal carcinoma (Table 1). All the tu-
mors were classified histologically as adenocarcinomas
by a pathologist. Consent was given by the patients for
the use of the tissue for experimental purposes, and in-
vestigations were approved by the ethical committee of
the Haukeland University Hospital, Bergen, Norway.
The specimen obtained at surgery were immediately
transferred aseptically to a test tube containing growth
medium: Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum (FCS), four times the
prescribed concentration of nonessential amino acids,
4 mM L-glutamine, penicillin (100 IU/ml), streptomycin
(100 μg/ml) and Fungin™ (10 μg/ml) (Bio Whittaker,
Verviers, Belgium).
Cell culture and spheroid growth
Specimen selected for three-dimensional (spheroid) cul-
ture were cut, minced, and incubated in 75-cm2 agar-
coated tissue culture flasks (Nunc, Roskilde, Denmark)
with 30 ml growth medium (described above). The
growth medium was changed every second day. After
2–5 days of culture in a standard tissue culture incuba-
tor (5% CO2, 100% air humidity), the tissue fragments
formed multicellular spheroids. Following 5 days of cul-
ture, individual spheroids (150 to 500 μm in diameter)
from 12 different patients were transferred with a sterile
Pasteur pipette from the culture flasks into 16-mm
agar-coated multiwell dishes with 2 ml growth medium.
Spheroid size was estimated during a period of 20 days,
using an inverted microscope with a calibrated reticle in
the eyepiece. All further experiments, including proteo-
mics were performed after 10 days of culture.
Electron microscopy
Five spheroids from three tumors were collected, in
each case, for transmission electron microscopy (TEM)
or scanning electron microscopy (SEM) study. Spher-
oids were fixed for 3 hours in 2% glutaraldehyde in
0.1 M sucrose-adjusted cacodylate buffer (pH 7.4; 300 ±
10 mOsmol). Post fixation was performed for 1 hour in 1%
OsO4 using the same buffer. The specimens were dehy-
drated with ethanol in concentrations increasing to 100%.
For TEM, embedding in Epon 812 was performed by
using graded additions of Epon-propylenoxide mixtures.
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3 days. Sections (60 nm thick) were cut with a diamond
knife on a Reichert Ultracut E ultramicrotome (Leica,
Buffallo, NY), collected on 200-mesh copper grids, and
examined in a Jeol 1230 transmission electron micro-
scope (Jeol, Tokyo, Japan) operated at 80 kV.
For SEM, the specimens were critical-point dried with
CO2. They were then carefully mounted on stubs using
tape and silver conductive paint. The specimens were
coated with gold in a vacuum evaporator and examined
with a Jeol JSM -7400 F Scanning Electron Microscope
(Jeol, Tokyo, Japan).
Light microscopy and immunohistochemistry
Part of collected material (Table 1) was routinely fixed
for 48–72 hours (tumor tissue) or 12–24 hours (spher-
oids) in 4% formaldehyde solution, and embedded in
paraffin. 5-μm- sections were hematoxylin and eosin
(H&E) stained for light microscopical investigation.
For immunohistochemical (IHC) analyses, all block-
ing and staining materials were from Dako (Glostrup,
Denmark) unless stated otherwise. Paraffin sections
were dewaxed and rehydrated. The slides were heated
in a microwave oven for 2 min at 1000 W, then 18 min at
200 W, in citrate buffer for antigen retrieval. Endogenous
peroxidase activity was blocked with peroxidase block for
10 min. After washing with Tris-buffered saline (TBS)
for 3 × 3 min, protein block was applied for 20 min,
followed by primary antibodies for 45 min in a humid
chamber at room temperature and sections were
washed for 3 × 3 min with TBS. Envision system was
used for visualization of antibody binding, with 3,3’-
diaminobenzidine (DAB) as a chromogen. All sections
were then counterstained with haematoxylin and mounted
with Entellan mounting medium (Merck, Darmstadt,
Germany).
The following antibodies and dilutions were used: anti-
cytokeratin 20, 1:20 (Genetex, San Antonio, TX, USA),
anti-vimentin, 1:100 (Dako, Glostrup, Denmark), anti-
CD68, 1:50 (Dako, Glostrup, Denmark), anti-podoplanin,
1:100 (Acris, Hiddenhausen, Germany), Ki-67, 1:100, anti-
PARP1, 1:100 (Bethyl, Antwerpen, Belgium), anti-Rac1,
1:50 (Chemicon, Overijse, Belgium), anti-β-catenin, 1:200
(Chemicon, Overijse, Belgium), anti-CD44 and anti-CD24,
1:50 (BD Biosciences, San Jose, CA, USA), anti-LAMA4
and anti-CDH1, 1:50 (Sigma Aldrich, Taufkirchen, Germany).
Label-free proteomics by GeLC-MS/MS and spectral
counting
Tissue lysis and gel electrophoresis
Three pairs of CRC biopsy samples and corresponding
spheroid samples (uniformly 10 days in culture) were
lysed in lysis buffer (per 100 mg tissue, one ml buffer
containing 7 M urea, 2 M thiourea, 4% (w/v) CHAPS,and 10 μl/ml protease inhibitor mix (Amersham Biosci-
ences, Piscataway, NJ, USA)). Thirty μg protein of each
sample was separated in parallel on a 10% SDS-PAGE
gel. The gel was fixed and stained with Coomassie Bril-
liant Blue, and each gel lane was sliced in 16 pieces
(see Additional file 2: Figure S2). Proteins in the gel
pieces were in-gel digested, and tryptic peptides ex-
tracted, as described elsewhere [92].
NanoLC-MSMS
The nanoLC-MS/MS workflow has been described be-
fore [45]. In brief, tryptic peptide fractions were injected
on a nano-LC system (Ultimate 3000, Dionex LC-
Packings, Amsterdam, The Netherlands) equipped with
a 20 cm × 75 μm i.d.fused silica column custom packed
with 3 μm 120 Å ReproSil Pur C18 aqua (Dr. Maisch,
GMBH, Ammerbuch-Entringen, Germany). After injec-
tion, peptides were trapped at 30 μL/min on a 5 mm ×
300 μm i.d. Pepmap C18 cartridge (Dionex LCPackings,
Amsterdam, The Netherlands) at 2% buffer B (buffer A,
0.05% formic acid in MQ; buffer B, 80% ACN and 0.05%
formic acid in MQ) and separated at 300 nL/min with a
10-40% buffer B gradient in 60 min.. Eluting peptides
were ionized in a Nanomate Triversa Chip-based nanos-
pray source using a Triversa LC coupler (Advion, Ithaca,
NJ), and MS and MS/MS spectra were recorded on-line
using an LTQ-FTICR mass spectrometer (ThermoFisher,
Bremen, Germany).
Data analysis
Searching of MS and MS/MS data against version 3.31
of the human IPI (International Protein Index) database
(67 511 entries), and spectral count analysis for relative
quantification were performed as detailed before [45]. At
the peptide level, only peptide identifications with a
probability of >95% were considered, and at the protein
level, only protein identifications with a probability
of >99% and with at least two peptides identified in
at least one of the samples were retained. Differential ana-
lysis of proteins in CRC tissue lysates versus corresponding
spheroid lysates was performed by a pair-wise comparison
of normalized spectral counts [72] where proteins with an
FC >1.5 in each of the 3 pairs were subjected to further
in silico analysis by protein network analysis and gene
ontology mining (see below).
Bioinformatics analysis
Identifier mapping
Using the human IPI identifiers of identified proteins,
gene symbols were checked/retrieved using data from
the European Bioinformatics Institute (EBI) IPI web-
page (ftp://ftp.ebi.ac.uk/pub/databases/IPI) or, if the IPI
identifier was no longer available in that repository,
from the EBI Sequence Retrieval System (SRS) webpage
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(neither of the two databases are no longer maintained)
combined with a standard protein BLAST (blastp) search
on the National Center for Biotechnology Information
(NCBI) website (http://blast.ncbi.nlm.nih.gov). Subse-
quently, all gene symbols were mapped to official gene
symbols using data from the HUGO Gene Nomenclature
Committee (HGNC) website (http://www.genenames.org)
Analysis of protein-protein interaction networks
Lists of gene symbols associated with proteins that
were up- or down-regulated, were analyzed with the
SearchTool for the Retrieval of Interacting Genes/Proteins
(STRING; version 8.3, http://string.embl.de). Protein-
protein interaction (PPI) data were retrieved with default
settings, allowing for experimentally verified as well as
predicted PPIs. The results were exported as a text file
and imported in the Cytoscape network analysis and
visualization tool (version 2.8.1; http://www.cytoscape.
org) [48]). Nodes were colored according to FC, and
sized according to the number of edges. In the case of
up-regulated proteins, proteins associated with acute
phase reactions coagulation, or the complement cas-
cade, as indicated by a preliminary gene ontology ana-
lysis (see below), were removed. These proteins are
listed in Additional file 4: Table S1.
Gene ontology mining
Complete networks or subclusters were analyzed within
Cytoscape, using the BINGO plug-in (version 2.44; http://
apps.cytoscape.org/apps/bingo; [49]). Default settings were
used (hypergeometric testing, Benjamini and Hochberg
False Discovery Rate (FDR) correction, P < 0.05), and the
whole data set was used as a reference set.
Additional files
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time in culture. Figure 1B. Proliferation Index of colorectal tumors and
corresponding spheroids.
Additional file 2: Figure S2. SDS PAGE gel image showing separation
pattern of tumor and corresponding spheroid proteins.
Additional file 3: Figure S3. Venn diagrams showing the overlap of
protein identifications accross biological samples.
Additional file 4: Table S1. Up-regulated nodes deleted from Figure 5
(Acute phase/coaggulation/complement cascade associated).
Additional file 5: Table S2. Comparison of parental CRC tissue (CRC) vs
derived spheroids (SPH) (paired samples) - All Data.
Additional file 6: Table S3A-D. Gene Ontology representation by
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Additional file 7: Table S4. Comparison of parental CRC tissue (CRC) vs
derived spheroids (SPH) (paired samples) - Proteins exhibiting Fold
Change > 1.5-fold in at least 2 out of 3 CRC/SPH pairs.
Competing interests
The authors’ declare that they have no competing interests.Authors’ contributions
UR, SPN and CRJ have made substantial contributions to conception and
design of the study, analysis and interpretation of data, have been involved in
drafting the manuscript, revising it critically for important intellectual content
and have given final approval of the version to be published. UR, JCK, SP, SB, FF,
ES, TVP were involved in acquisition of data, analysis and interpretation of data
and in drafting the manuscript and revising it critically. KS, RM were involved in
critical revision of the study and have given final approval of the version to be
published. All authors read and approved the final manuscript.
Acknowledgements
This work was funded by Fonds National de Recherche (FNR) to UR and SPN,
by European Commission 6th framework program (Angiotargeting project,
Contract 504743); by CRP-Santé and the Research Ministry (Ministère de la
Culture, de l’Enseignement Supérieur et de la Recherche) of Luxembourg
and by the VU Medical Center, Cancer Center Amsterdam (to JCK, SP, TVP,
and CRJ and for the proteomics infrastructure).
Author details
1NorLux Neuro-Oncology Laboratory, Department of Oncology, CRP-Santé,
Luxembourg, Luxembourg. 2OncoProteomics Laboratory, Department of
Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical
Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
3Department of Research and Development, Blood Transfusion Center of
Slovenia, Ljubljana, Slovenia. 4Department of Biomedicine, University of
Bergen, Bergen, Norway. 5Haukeland University Hospital, Bergen, Norway.
6Department of Surgery, Haraldsplass Deaconal Hospital, University of
Bergen, Bergen, Norway. 7Institute of Pathology, Faculty of Medicine,
University of Ljubljana, Ljubljana, Slovenia.
Received: 21 October 2013 Accepted: 9 June 2014
Published: 11 July 2014
References
1. Jacks T, Weinberg RA: Taking the study of cancer cell survival to a new
dimension. Cell 2002, 111:923–925.
2. Santini MT, Rainaldi G: Three-dimensional spheroid model in tumor
biology. Pathobiology 1999, 67:148–157.
3. Sutherland RM: Cell and environment interactions in tumor microregions:
the multicell spheroid model. Science 1988, 240:177–184.
4. Yamada KM, Clark K: Cell biology: survival in three dimensions. Nature
2002, 419:790–791.
5. Achilli TM, Meyer J, Morgan JR: Advances in the formation, use and
understanding of multi-cellular spheroids. Expert opinion on biological
therapy 2012, 12:1347–1360.
6. Chong BE, Yan F, Lubman DM, Miller FR: Chromatofocusing nonporous
reversed-phase high-performance liquid chromatography/electrospray
ionization time-of-flight mass spectrometry of proteins from human breast
cancer whole cell lysates: a novel two-dimensional liquid chromatography/
mass spectrometry method. Rapid Commun Mass Spectrom 2001,
15:291–296.
7. Labarbera DV, Reid BG, Yoo BH: The multicellular tumor spheroid model
for high-throughput cancer drug discovery. Expert opinion on drug
discovery 2012, 7:819–30.
8. Mueller-Klieser W: Multicellular spheroids: A review on cellular aggregates
in cancer research. J Cancer Res Clin Oncol 1987, 113:101–122.
9. Sutherland RM, Durand RE: Growth and cellular characteristics of multicell
spheroids. Recent Result Cancer Res 1984, 95:24–49.
10. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH,
Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR,
Kemper K, Richel DJ, Stassi G, Medema JP: Wnt activity defines colon
cancer stem cells and is regulated by the microenvironment. Nat Cell Biol
2010, 12:468–476.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J,
Weinberg RA: The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell 2008, 133:704–715.
12. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M,
Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H: Identification of
stem cells in small intestine and colon by marker gene Lgr5. Nature 2007,
449:1003–1007.
Rajcevic et al. Proteome Science 2014, 12:39 Page 13 of 14
http://www.proteomesci.com/content/12/1/3913. Ritsma L, Ellenbroek SI, Zomer A, Snippert HJ, de Sauvage FJ, Simons BD,
Clevers H, van Rheenen J: Intestinal crypt homeostasis revealed at
single-stem-cell level by in vivo live imaging. Nature 2014, 507:362–365.
14. Sato T, Clevers H: Growing self-organizing mini-guts from a single intestinal
stem cell: mechanism and applications. Science 2013, 340:1190–1194.
15. Sato T, Katagiri K, Gohbara A, Inoue K, Ogonuki N, Ogura A, Kubota Y,
Ogawa T: In vitro production of functional sperm in cultured neonatal
mouse testes. Nature 2011, 471:504–507.
16. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG: Colorectal
cancer stem cells. Stem Cells 2012, 30:363–371.
17. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A,
Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci U S A 2007, 104:10158–10163.
18. O’Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature
2007, 445:106–110.
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,
De Maria R: Identification and expansion of human colon-cancer-initiating
cells. Nature 2007, 445:111–115.
20. Munoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S,
Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom
OJ, van Es JH, Barker N, van Oudenaarden A, Mohammed S, Heck AJ,
Clevers H: The Lgr5 intestinal stem cell signature: robust expression of
proposed quiescent ‘+ 4’ cell markers. EMBO J 2012, 31:3079–3091.
21. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP: Cancer stem
cells–old concepts, new insights. Cell Death Differ 2008, 15:947–958.
22. Lassmann S, Opitz OG: The new look of colorectal cancer stem cells.
Gastroenterology 2008, 134:1262–1264.
23. Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A,
Nijkamp MW, Steller EJ, Jimenez CR, Clevers H, Borel Rinkes IH, Kranenburg
O: Differentiated human colorectal cancer cells protect tumor-initiating
cells from irinotecan. Gastroenterology 2011, 141:269–278.
24. Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H,
Ogawa K, Shirai T: Gpx2 is an overexpressed gene in rat breast cancers
induced by three different chemical carcinogens. Cancer Res 2007,
67:11353–11358.
25. Espina C, Cespedes MV, Garcia-Cabezas MA, del Pulgar MT G, Boluda A, Oroz
LG, Benitah SA, Cejas P, Nistal M, Mangues R, Lacal JC: A critical role for
Rac1 in tumor progression of human colorectal adenocarcinoma cells.
Am J Pathol 2008, 172:156–166.
26. Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and
malignant behavior. Curr Opin Cell Biol 2007, 19:150–158.
27. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005,
434:843–850.
28. Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO: Multicellular tumor
spheroids from human gliomas maintained in organ culture. J Neurosurg
1990, 72:463–475.
29. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O: Growth of precultured
human glioma specimens in nude rat brain. J Neurosurg 1999, 90:125–132.
30. Fehlauer F, Muench M, Smid EJ, Slotman B, Richter E, Van der Valk P, Sminia
P: Combined modality therapy of gemcitabine and irradiation on human
glioma spheroids derived from cell lines and biopsy tissue. Oncol Rep
2006, 15:97–105.
31. Fjellbirkeland L, Bjerkvig R, Laerum OD: Tumour fragment spheroids from
human non-small-cell lung cancer maintained in organ culture. Virchows
Arch 1995, 426:169–178.
32. Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelieres FP,
Bertrand F, Dargere D, Massonnet G, Marangoni E, Gayet B, Pocard M,
Bieche I, Poupon MF, Bellet D, Dangles-Marie V: Newly characterised
ex vivo colospheres as a three-dimensional colon cancer cell model of
tumour aggressiveness. Br J Cancer 2009, 101:473–482.
33. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R,
Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, Chekenya M, Peters
H, Lende G, Kalland KH, Oyan AM, Petersen K, Jonassen I, van der Kogel A,
Feuerstein BG, Terzis AJ, Bjerkvig R, Enger PO: Angiogenesis-independent
tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S
A 2006, 103:16466–16471.
34. Kranenburg O, Emmink BL, Knol J, van Houdt WJ, Rinkes IH, Jimenez CR:
Proteomics in studying cancer stem cell biology. Expert Rev Proteomics
2012, 9:325–336.35. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van
Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H: Long-term
expansion of epithelial organoids from human colon, adenoma,
adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011,
141:1762–1772.
36. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden
CJ, Ylstra B, Leenstra S: The genomic profile of human malignant glioma
is altered early in primary cell culture and preserved in spheroids.
Oncogene 2008, 27:2091–2096.
37. Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato
T, Stange DE, Begthel H, van den Born M, Danenberg E, van den Brink S,
Korving J, Abo A, Peters PJ, Wright N, Poulsom R, Clevers H: Lgr5(+ve) stem
cells drive self-renewal in the stomach and build long-lived gastric units
in vitro. Cell Stem Cell 2010, 6:25–36.
38. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M, Sato T,
Hamer K, Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H:
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven
regeneration. Nature 2013, 494:247–250.
39. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van
Es JH, Abo A, Kujala P, Peters PJ, Clevers H: Single Lgr5 stem cells build
crypt-villus structures in vitro without a mesenchymal niche. Nature 2009,
459:262–265.
40. Blaydon DC, Ishii Y, O’Toole EA, Unsworth HC, Teh MT, Ruschendorf F,
Sinclair C, Hopsu-Havu VK, Tidman N, Moss C, Watson R, de Berker D, Wajid
M, Christiano AM, Kelsell DP: The gene encoding R-spondin 4 (RSPO4), a
secreted protein implicated in Wnt signaling, is mutated in inherited
anonychia. Nat Genet 2006, 38:1245–1247.
41. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q: R-spondins function as ligands
of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin
signaling. Proc Natl Acad Sci U S A 2011, 108:11452–11457.
42. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P,
Haegebarth A, Peters PJ, van de Wetering M, Stange DE, van Es JE,
Guardavaccaro D, Schasfoort RB, Mohri Y, Nishimori K, Mohammed S, Heck
AJ, Clevers H: Lgr5 homologues associate with Wnt receptors and
mediate R-spondin signalling. Nature 2011, 476:293–297.
43. Kim KA, Kakitani M, Zhao J, Oshima T, Tang T, Binnerts M, Liu Y, Boyle B,
Park E, Emtage P, Funk WD, Tomizuka K: Mitogenic influence of human
R-spondin1 on the intestinal epithelium. Science 2005, 309:1256–1259.
44. Albrethsen J, Knol JC, Piersma SR, Pham TV, de Wit M, Mongera S, Carvalho
B, Verheul HM, Fijneman RJ, Meijer GA, Jimenez CR: Subnuclear proteomics
in colorectal cancer: identification of proteins enriched in the nuclear
matrix fraction and regulation in adenoma to carcinoma progression.
Mol Cell Proteomics 2010, 9:988–1005.
45. Piersma SR, Fiedler U, Span S, Lingnau A, Pham TV, Hoffmann S, Kubbutat MH,
Jimenez CR: Workflow comparison for label-free, quantitative secretome
proteomics for cancer biomarker discovery: method evaluation, differential
analysis, and verification in serum. J Proteome Res 2010, 9:1913–1922.
46. Chen WS, Chen CC, Chen LL, Lee CC, Huang TS: Secreted heat shock
protein 90alpha (HSP90alpha) induces nuclear factor-kappaB-mediated
TCF12 protein expression to down-regulate E-cadherin and to enhance
colorectal cancer cell migration and invasion. J Biol Chem 2013,
288:9001–9010.
47. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P,
Doerks T, Stark M, Muller J, Bork P, Jensen LJ, von Mering C: The STRING
database in 2011: functional interaction networks of proteins, globally
integrated and scored. Nucleic Acids Res 2011, 39:D561–568.
48. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T: Cytoscape 2.8: new
features for data integration and network visualization. Bioinformatics
2011, 27:431–432.
49. Maere S, Heymans K, Kuiper M: BiNGO: a Cytoscape plugin to assess
overrepresentation of gene ontology categories in biological networks.
Bioinformatics 2005, 21:3448–3449.
50. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U,
Goodell MA, Brenner MK: A distinct “side population” of cells with high
drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004,
101:14228–14233.
51. Ju Z, Rudolph KL: Telomeres and telomerase in cancer stem cells. Eur J
Cancer 2006, 42:1197–1203.
52. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH,
Bronner-Fraser M, Kornblum HI: Cancerous stem cells can arise from
pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100:15178–15183.
Rajcevic et al. Proteome Science 2014, 12:39 Page 14 of 14
http://www.proteomesci.com/content/12/1/3953. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB:
Identification of a cancer stem cell in human brain tumors. Cancer Res
2003, 63:5821–5828.
54. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM,
Cusimano MD, Dirks PB: Identification of human brain tumour initiating
cells. Nature 2004, 432:396–401.
55. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL,
Yu JS: Isolation of cancer stem cells from adult glioblastoma multiforme.
Oncogene 2004, 23:9392–9400.
56. Kuipers MA, Stasevich TJ, Sasaki T, Wilson KA, Hazelwood KL, McNally JG,
Davidson MW, Gilbert DM: Highly stable loading of Mcm proteins onto
chromatin in living cells requires replication to unload. J Cell Biol 2011,
192:29–41.
57. Moldovan GL, Pfander B, Jentsch S: PCNA, the maestro of the replication
fork. Cell 2007, 129:665–679.
58. Stoimenov I, Helleday T: PCNA on the crossroad of cancer. Biochem Soc
Trans 2009, 37:605–613.
59. Kwon SH, Florens L, Swanson SK, Washburn MP, Abmayr SM, Workman JL:
Heterochromatin protein 1 (HP1) connects the FACT histone chaperone
complex to the phosphorylated CTD of RNA polymerase II. Genes Dev
2010, 24:2133–2145.
60. Vakoc CR, Mandat SA, Olenchock BA, Blobel GA: Histone H3 lysine 9
methylation and HP1gamma are associated with transcription
elongation through mammalian chromatin. Mol Cell 2005, 19:381–391.
61. Gant TM, Wilson KL: Nuclear assembly. Annu Rev Cell Dev Biol 1997,
13:669–695.
62. Ahmad K, Henikoff S: The histone variant H3.3 marks active chromatin
by replication-independent nucleosome assembly. Mol Cell 2002,
9:1191–1200.
63. Santenard A, Ziegler-Birling C, Koch M, Tora L, Bannister AJ, Torres-Padilla
ME: Heterochromatin formation in the mouse embryo requires critical
residues of the histone variant H3.3. Nat Cell Biol 2010, 12:853–862.
64. Delbarre E, Jacobsen BM, Reiner AH, Sorensen AL, Kuntziger T, Collas P:
Chromatin environment of histone variant H3.3 revealed by quantitative
imaging and genome-scale chromatin and DNA immunoprecipitation.
Mol Biol Cell 2010, 21:1872–1884.
65. Ohm JE, Baylin SB: Stem Cell Epigenetics. Regulatory Networks in Stem
Cells. In Regulatory Networks in Stem Cells. Stem Cell Biology and Regenerative
Medicine. Part III. Edited by Rajasekhar VK, Vemuri MC. New York: Humana
Press; 2009:235–246.
66. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation
of histone acetylation and transcription by INHAT, a human cellular
complex containing the set oncoprotein. Cell 2001, 104:119–130.
67. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M: The oncoprotein Set/
TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active
demethylation of DNA, integrating DNA methylation and transcriptional
silencing. J Biol Chem 2002, 277:25026–25031.
68. Ji Y, Tulin AV: The roles of PARP1 in gene control and cell differentiation.
Curr Opin Genet Dev 2010, 20:512–518.
69. Rathaus M, Lerrer B, Cohen HY: DeubiKuitylation: a novel DUB enzymatic
activity for the DNA repair protein, Ku70. Cell Cycle 2009, 8:1843–1852.
70. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL: NAD + −dependent
modulation of chromatin structure and transcription by nucleosome
binding properties of PARP-1. Cell 2004, 119:803–814.
71. Hassa PO, Hottiger MO: The diverse biological roles of mammalian PARPS,
a small but powerful family of poly-ADP-ribose polymerases. Front Biosci
2008, 13:3046–3082.
72. Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG,
Fratantoni SA, Pronk A, Clevers H, Borel Rinkes IH, Jimenez CR, Kranenburg
O: Comparative proteomics of colon cancer stem cells and differentiated
tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell
Proteomics 2011, 10:M111 011353.
73. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan
V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y: Confirmation of gene
expression-based prediction of survival in non-small cell lung cancer.
Clin Cancer Res 2008, 14:8213–8220.
74. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T,
Hilsenbeck S, Wong H, Osborne CK, O’Connell P, Chang JC: Gene expression
patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan)
(AC) response and resistance. Breast Cancer Res Treat 2006, 95:229–233.75. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674.
76. Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer’s Achilles’ heel.
Cancer Cell 2008, 13:472–482.
77. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev
Cancer 2011, 11:85–95.
78. Bensinger SJ, Christofk HR: New aspects of the Warburg effect in cancer
cell biology. Semin Cell Dev Biol 2012, 23:352–361.
79. Yang H, Dou Y, Zheng X, Tan Y, Cheng J, Li L, Du Y, Zhu D, Lou Y: Cysteinyl
leukotrienes synthesis is involved in aristolochic acid I-induced apoptosis
in renal proximal tubular epithelial cells. Toxicology 2011, 287:38–45.
80. Krasnikov BF, Chien CH, Nostramo R, Pinto JT, Nieves E, Callaway M, Sun J,
Huebner K, Cooper AJ: Identification of the putative tumor suppressor
Nit2 as omega-amidase, an enzyme metabolically linked to glutamine
and asparagine transamination. Biochimie 2009, 91:1072–1080.
81. Jakoby WB, Ziegler DM: The enzymes of detoxication. J Biol Chem 1990,
265:20715–20718.
82. Yoshida A, Rzhetsky A, Hsu LC, Chang C: Human aldehyde dehydrogenase
gene family. Eur J Biochem 1998, 251:549–557.
83. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM: Targeted
inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001,
276:20673–20678.
84. Piredda L, Farrace MG, Lo Bello M, Malorni W, Melino G, Petruzzelli R,
Piacentini M: Identification of ‘tissue’ transglutaminase binding proteins
in neural cells committed to apoptosis. FASEB J 1999, 13:355–364.
85. Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria in cancer cells: what
is so special about them? Trends Cell Biol 2008, 18:165–173.
86. Clevers H, Nusse R: Wnt/beta-Catenin Signaling and Disease. Cell 2012,
149:1192–1205.
87. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S,
Heck AJ, Maurice MM, Mahmoudi T, Clevers H: Wnt Signaling through
Inhibition of beta-Catenin Degradation in an Intact Axin1 Complex. Cell
2012, 149:1245–1256.
88. Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y,
Imai K, Hirohashi S, Yamada T: Ku70 and poly (ADP-ribose) polymerase-1
competitively regulate beta-catenin and T-cell factor-4-mediated gene
transactivation: possible linkage of DNA damage recognition and Wnt
signaling. Cancer Res 2007, 67:911–918.
89. Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S: Poly (ADP-ribose)
polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin
complex. Gastroenterology 2005, 128:1919–1936.
90. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair
R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale
NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii
S: CD133 expression is not restricted to stem cells, and both CD133+
and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest
2008, 118:2111–2120.
91. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra
J, Pals ST, Mehmet H, Stassi G, Medema JP: The AC133 epitope, but not
the CD133 protein, is lost upon cancer stem cell differentiation. Cancer
Res 2010, 70:719–729.
92. Jimenez CR, Huang L, Qiu Y, Burlingame AL: In-gel digestion of proteins
for MALDI-MS fingerprint mapping. Curr Protoc Protein Sci 2001, Chapter
16:Unit 16.14. doi:10.1002/0471140864.ps1604s14.
doi:10.1186/1477-5956-12-39
Cite this article as: Rajcevic et al.: Colorectal cancer derived organotypic
spheroids maintain essential tissue characteristics but adapt their
metabolism in culture. Proteome Science 2014 12:39.
